Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Completed PHASE3 INTERVENTIONAL NCT03272126

Importance of Dosing Regimen for the Effect of Vitamin D Supplementation

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Vitamin D is a hormone with effects not only on the skeleton, but on most tissues in the body. Lack of vitamin D is associated with cardio-vascular disease (CVD), type 2 diabetes, cancer, infectious and immunological diseases, as well as risk factors for these diseases. However, intervention studies with vitamin D have been inconclusive regarding diseases and risk factors. This could be due to inclusion of subjects already vitamin D sufficient, and short and underpowered studies. In addition, there are indications that the dosing regimens may be important, so that daily doses with vitamin D are more efficient than intermittent doses, which so far have been generally used. This could be related to the concentration of circulating and thereby intracellular vitamin D concentrations, which probably is dependent on daily vitamin D doses. This will be tested in the present study where 60 subjects will be randomized to vitamin D 160 000 once, vitamin D 4000 IU/day, or placebo for four weeks. The primary endpoints will be effects on serum hepcidin and plasma cathelicidin after 4 weeks, with effects on serum PTH, RNA expression and microRNA in peripheral blood, telomerase activity in peripheral blood mononuclear cells and the ration between serum 1,25(OH)2D and 24,25(OH)2D as secondary endpoints.

Interventions

Name: Vitamin D
Type: DRUG
Description: vitamin D given as bolus versus daily dosing
Name: Placebo
Type: DRUG
Description: identical looking as vitamin D

Primary Outcomes

Measure: Hepcidin change
TimeFrame: 4 weeks
Description: Difference between vitamin D given as a bolus 160 000IU vs 4000 IU regarding change in serum hepcidin

Trial Information

NCT ID

NCT03272126

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE3

Sponsor

University of Tromso

Last Updated

December 15, 2025